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Abstract: The management of renal cell carcinoma (RCC) has undergone significant changes 
during the past 10 years, with the treatment of metastatic RCC undergoing the most radical 
changes. These developments reflect an enhanced understanding of this tumor’s underlying 
biology, which was then translated into the development of a new treatment paradigm. Current 
therapeutic approaches for the management of patients with metastatic RCC utilize knowledge 
of histology, molecular abnormalities, clinical prognostic factors, the natural history of this 
malignancy, and the treatment efficacy and toxicity of available agents. The treatment options 
available for patients with metastatic RCC have changed dramatically over the past 6 years. 
Interferon-α and interleukin-2 were the previous mainstays of therapy, but since December 
2005, six new agents have been approved in the US for the treatment of advanced RCC. Three 
are multi-targeted tyrosine kinase inhibitors (TKI) including sunitinib, sorafenib, and pazopanib, 
two target the mammalian target of rapamycin (temsirolimus and everolimus), and one is a 
humanized monoclonal antibody (bevacizumab in combination with interferon-α). The current 
review focuses on the newest TKI available to treat patients with metastatic RCC, pazopanib. The 
development of this agent both preclinically and clinically is reviewed. The efficacy and safety 
data from the pivotal clinical trials are discussed, and the potential role of pazopanib in the treat-
ment of patients with metastatic RCC in comparison to other treatment alternatives is critically 
appraised. This agent has a favorable overall risk benefit, and the available data demonstrate 
efficacy in patients with metastatic RCC who are either treatment-naïve or cytokine refractory. 
It therefore represents another alternative for treatment of metastatic RCC patients.
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Introduction: management of metastatic renal  
cell carcinoma (RCC)
The management of RCC has undergone significant changes during the past 10 years. 
Surgical innovation has reduced morbidity and currently surgery utilizing less inva-
sive approaches which preserve efficacy are emphasized. The therapy for metastatic 
RCC has seen the greatest change, reflecting an enhanced understanding of this 
tumor’s underlying biology, which was then translated into the development of a new 
treatment paradigm.
RCC accounts for 2% to 3% of all malignant tumors, and is the sixth leading 
cause of death in the US. An estimated 58,000 new renal tumors were diagnosed in 
2010, with approximately 13,000 deaths reported.1 It is most common in the seventh 
decade of life, and a male to female predominance of 1.6 to 1.0 is present. Worldwide, 
the incidence of RCC is over 200,000 new cases annually, with over 100,000 deaths Cancer Management and Research 2011:3 submit your manuscript | www.dovepress.com
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per year.2 Active and passive cigarette smoking is the major 
recognized risk factor for RCC, with a relative risk (RR) of 
approximately two- to three-fold.3
Current therapeutic approaches for management of 
patients with metastatic RCC utilize knowledge of histology, 
molecular abnormalities, clinical prognostic factors, knowl-
edge of the natural history of RCC, and the treatment efficacy 
and toxicity of available agents (Figure 1). Histology plays a 
significant role in treatment outcome and selection. Epithelial 
RCC includes various histologic subtypes, which have unique 
morphologic and genetic characteristics. Clear cell RCC is the 
most common epithelial subtype, accounting for 75%–85% 
of these tumors, and arises from the proximal convoluted 
tubule. Importantly, over 80% of sporadic clear cell RCC 
are associated with defects in the von   Hippel-Lindau (VHL) 
gene.4 Additional gene mutations and deletions have been 
recently identified,5 however their importance and relevance 
are as yet unclear. The remaining subtypes of epithelial RCC 
are collectively referred to as non-clear cell carcinomas, with 
papillary RCC being the most common type (10%–15%). 
Understanding histologic subtypes and associated molecular 
alterations has provided the framework within which disease-
specific therapy has developed.
Approximately 2%–3% of cases of RCC are familial and 
several autosomal dominant syndromes have been described, 
each with a distinct genetic basis and phenotype.6 Most com-
mon is the VHL syndrome (1/36,000 births), characterized 
by the development of vascular tumors including clear cell 
RCC, hemangioblastomas of the central nervous system, 
and pheochromocytomas.7 The tumor suppressor gene 
responsible for this syndrome is located on chromosome 3 
(3p25-26).8 Patients with the VHL syndrome inherit a defect 
on one allele of the VHL gene, and acquire a defect in the 
remaining allele. The majority of patients with sporadic 
(noninherited) clear cell RCC acquire defects of both alleles 
of the VHL gene with resulting dysfunction of the VHL 
protein. In sporadic clear cell RCC, both the maternal and 
paternal VHL alleles are inactivated by acquired mutations. 
The VHL protein functions as a tumor suppressor, and is 
responsible for ubiquination and proteasome degradation of 
hypoxia-inducible factor (HIF), a regulator of the hypoxic 
response.9 Under hypoxia, or when VHL protein is nonfunc-
tional, it does not bind and inactivate HIF-α, resulting in its 
accumulation. This in turn activates transcription of a variety 
of hypoxia-inducible genes, including vascular endothelial 
growth factor (VEGF), platelet-derived growth factor-β 
Locally advanced or metastatic RCC (stage IV)
Factors influencing therapy choice:
• Histologic subtype (clear cell vs other)
• Molecular features
• Natural history of patient’s malignancy
• Prognostic factors
• Prior therapy: treatment naïve vs. 
refractory
• Treatment efficacy and toxicity
Surgery:
• Cytoreductive
nephrectomy
• Metastasectomy
(solitary, limited)
Systemic therapy:
• Multikinase inhibitors:
– Sunitinib
– Pazopanib
– Sorafenib
• Bevacizumab + IFN-α
• mTOR inhibitors:
–Everolimus
–Temsirolimus
• Cytokines: IL-2, IFN-α
• Chemotherapy
Palliative therapy:
• Radiotherapy
• Bisphosphonates
Figure 1 Flow diagram illustrating decision factors and therapeutic alternatives in patients with locally advanced and metastatic renal cell carcinoma.Cancer Management and Research 2011:3 submit your manuscript | www.dovepress.com
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(PDGF-β), transforming growth factor-α, and erythropoietin. 
Clear cell cancers are highly vascular, secondary in part to 
stimulation of tumor associated angiogenesis. VHL protein 
plays a pivotal role in the control of neoangiogenesis, and 
loss of VHL gene function results in enhanced secretion 
of VEGF, PDGF, and creation of the vascular phenotype 
characteristic of clear cell RCC.
Retrospective analysis of untreated metastatic RCC 
patients has identified clinical characteristics associated with 
differences in prognosis. An initial model was developed at 
Memorial Sloan-Kettering Cancer Center (MSKCC), and 
validated at the Cleveland Clinic.10,11 These risk criteria 
have now been utilized in a series of Phase III clinical trials. 
The five factors include low Karnofsky performance status 
(,80%), low serum hemoglobin, high corrected calcium, 
elevated lactate dehydrogenase, and short disease-free inter-
val (,1 year). Prognostic groups were defined as favorable 
(no factors), intermediate (#2 factors), and poor ($3 fac-
tors), with median overall survival (OS) of 28.0, 13.6, and 
4.6 months, respectively.10 Recently, these criteria have been 
reexamined, and alternate models proposed.12
Finally, an understanding of the natural history of RCC is 
critical in understanding the clinical course of metastatic RCC 
patients, and planning treatment. Issues such as management 
of synchronous metastatic disease, indolent disease patterns, 
long disease-free intervals in selected patients, patterns of 
metastatic disease, and the frequency of disease recurrence 
in sites such as the central nervous system and bone are 
important considerations. A complete discussion of these is 
beyond the scope of this review, and the reader is referred to 
recent reviews.13 In this context, a new treatment paradigm 
utilizing molecularly targeted agents has been developed for 
patients with metastatic clear cell RCC.
Treatment options for patients with metastatic RCC have 
changed dramatically over the past 6 years, and a new para-
digm has evolved. Interferon-α (INF-α) and   interleukin-2 
(IL-2) were the previous mainstays of therapy,14 but since 
December 2005, six new agents have been approved in 
the US for the treatment of advanced RCC. Three are 
  multi-targeted tyrosine kinase inhibitors (TKIs) including 
sunitinib,15 sorafenib,16 and pazopanib,17 two target the mam-
malian target of rapamycin (temsirolimus18 and everolimus19), 
and one is a humanized monoclonal antibody (bevacizumab 
in combination with INF-α) which targets VEGF.20 Sunitinib 
has emerged as the standard-of-care for treatment-naïve 
RCC patients, with the recent approvals of the bevacizumab 
and IFN-α combination and pazopanib providing additional 
options for frontline therapy.
Pazopanib: mode of action,  
clinical pharmacology
Preclinical
Pazopanib (GW786034; VotrientTM, GlaxoSmithKline, NC) 
is an indazolylpyrimidine 5-[[4-{(2, 3-dimethyl-2H-indazol-
6-yl)methylamino}-2-pyrimidinyl]amino]-2-methylbenze-
nesulfonamide that is orally bioavailable (Figure 2). It was 
discovered during the screening of samples which included 
agents which inhibited the activities of VEGF receptor 
(VEGFR).22 A monohydrochloride pyrimidine containing 
compound, pazopanib, which demonstrated both a favorable 
pharmokinetic profile and in vivo antitumor efficacy, was 
then selected for further development. When pazopanib was 
administered orally, optimal antitumor in vivo activity was 
noted. Since pazopanib demonstrated potency and selective 
inhibition of VEGFR, it was selected for further preclinical 
and clinical development.22,23
Kumar et al24 investigated the in vitro and in vivo pharma-
codynamics of pazopanib. The inhibition of VEGF-induced 
phosphorylation of a wide variety of kinases in vitro was 
characterized. Kinases targeted for study included VEGFR1, 
VEGFR2 (from human, dog, mouse, and rat), VEGFR3, 
and a number of non-VEGFR kinases. Pazopanib inhibited 
the VEGFR kinase family, including VEGFR1, VEGFR2, 
and VEGFR3, and had similar activities against PDGFRα, 
PDGFRβ, and c-Kit (Table 1). Modest activity against 
fibroblast growth factor receptor 1, fibroblast growth factor 
receptor 3, and the c-fms receptor was also noted. It appeared 
from these data that pazopanib demonstrated modest selec-
tivity in vitro.
Preclinical evaluation to assess the optimal pazopanib 
concentrations required for in vivo antitumor/antiangiogenic 
activity was also conducted.24 In vivo inhibition of VEGFR2 
phosphorylation in immunocomprised mice was assessed. 
Various transplantable tumor cell suspensions (HT29, A375P, 
PC3, Caki-2) were injected subcutaneously. In view of the 
poor solubility of pazopanib, sufficient parenteral drug levels 
were not achieved and a related compound, GW771806, with 
a kinase inhibitory spectrum similar to pazopanib was sub-
stituted. In vivo, Cmax, and drug exposure (area under curve 
[AUC]) did not appear to correlate with activity.
Pazopanib was further evaluated using oral administra-
tion. Dose-dependent growth inhibition of all tumor xeno-
grafts was reported, however, Caki-2, a RCC cell line, was 
the most sensitive to pazopanib (77% inhibition at 10 mg/kg 
dose, and complete inhibition at 100 mg/kg dose).
The effects of pazopanib on VEGF-induced VEGFR2 
phosphorylation were then evaluated in vivo utilizing Cancer Management and Research 2011:3 submit your manuscript | www.dovepress.com
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endothelial cells from mouse lungs and tumors. In the tumor 
xenograft studies, VEGFR2 phosphorylation of endothelial 
cells was not seen, perhaps reflecting low vessel density. 
In contrast, a single per os dose of 30 mg/kg of pazopanib 
inhibited lung endothelial VEGFR2 phosphorylation for 
over 8 hours. This dose corresponded to a plasma concentra-
tion .40 µmol/L. Below this, inhibition of VEGFR2 phos-
phorylation was minimal. These preclinical studies suggested 
pazopanib concentrations of $40 µmol/L would probably 
be required for optimal VEGFR2 inhibition, whereas the in 
vitro data suggested an IC50 of 0.02 µmol/L. The reasons 
for this difference may be related to the significant protein 
binding of pazopanib.
Clinical
The pharmacokinetics of pazopanib in human subjects 
were investigated in a Phase I clinical trial25 in which 63 
patients with refractory solid tumors received escalating 
doses of pazopanib (50 mg three times weekly, 50–2000 mg 
daily, and 300–400 mg twice daily). Plasma pazopanib was 
detected at all dose levels, however, its oral bioavailability 
and solubility are low, and therefore, absorption at doses 
above 800 mg once daily was limited. Geometric mean 
pazopanib t½ values ranged from 18.1 hours to 52.3 hours. 
In patients receiving 800 mg once daily the mean t½ was 
30.9 hours. Mean Cmax and AUC0–24 on day 1 increased 
with increasing pazopanib dose levels. The highest values 
were seen in patients receiving 2000 mg daily. No evidence 
of drug accumulation was observed, and the steady-state 
exposure plateaued at 800 mg daily. These data suggested 
increasing pazopanib doses above 800 mg would not 
produce increased plasma drug levels. This schedule and 
dose were subsequently selected for Phase II and Phase III 
clinical trials.
Molecular formula: C21H23N7O2S•HCl 
Chemical name: 5-[[4-{(2,3-dimethyl-2H-indazol-6-yl)methylamino}-
2pyrimidinyl]amino]-2-methylbenzenesulfonamide monohydrochloride
Molecular weight: 473.99
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Figure 2 Molecular structure and chemical name of pazopanib.21
Table 1 In vitro activity of pazopanib in purified human kinase 
and cell-based receptor assays24
Activity against  
purified kinasesa
Cellular IC50: inhibition of 
ligand-induced receptor 
autophosphorylationb
Kinase or 
receptor
Pazopanib (nM) Cells Pazopanib 
iC50 (nM)
veGFR1 15 ND ND
veGFR2 8 HUveC 8
veGFR3 10 ND ND
PDGFRα 30 HFF 3
PDGFRβ 14 ND ND
c-Kit 2.4 NCi-H526 2.6
Flt-3 230 RS4;11 $1,000
Notes: aTyrosine kinase inhibitors tested in a panel of kinases at 03 and 10.0 µM 
utilizing  Profile  Express  (Millipore,  Billerica,  MA);  bcellular  inhibitory  activity  of 
tyrosine  kinase  inhibitors  against  wild-type  receptors  on  cells  noted  employing 
autophosphorylation inhibition.
Abbreviations: iC, inhibitory concentrations; veGFR, vascular endothelial growth 
factor receptor; PDGFR, platelet derived growth factor receptor; HUveC, human 
umbilical vein endothelial cells; ND, not done.Cancer Management and Research 2011:3 submit your manuscript | www.dovepress.com
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Pazopanib absorption increases when administered with 
food, therefore, it is administered in the fasting state.26 It is 
highly protein bound (.98.8%)24 and is metabolized by cyto-
chrome P450 (CYP) 3A4, and to a lesser degree by CYP1A2 
and CYP2C8.26 Potential interactions with CYP3A4 inhibi-
tors or inducers are possible, but none have been reported. 
Pazopanib is excreted primarily via the fecal route. Studies 
estimate less than 4% is excreted in the urine, and therefore 
impaired renal function is not likely to alter systemic expo-
sure.26 Pazopanib metabolites are produced at low levels, 
and probably do not contribute to drug activity. Finally, age, 
race, and gender are reported to have minimal effects on the 
pharmacokinetics of pazopanib,26 however, formal studies in 
Asians have not been reported.
Pazopanib: clinical trials
A series of clinical trials investigating the toxicity and effi-
cacy of pazopanib have been reported. These include a Phase 
I trial in solid tumor patients, two large randomized trials in 
patients with advanced RCC, and a series of Phase I and II 
studies to assess pazopanib in various RCC patient subsets, 
or in combination with other targeted agents.
Phase i trial
The Phase I pazopanib clinical trial demonstrated that it 
was well tolerated and had antitumor activity.25 Mild-to-
moderate hypertension, diarrhea, hair depigmentation, and 
nausea were observed. Hypertension was the most frequent 
grade 3 adverse event. In 12 patients with metastatic RCC, 
a partial response was seen in two, stable disease in four, 
and progressive disease in four. These results demonstrated 
pazopanib was tolerated over a range of doses. The 800 mg 
once daily dose was recommended for future studies.
Phase ii randomized discontinuation  
trial (RDT)
Based on this initial information, a Phase II RDT27 was 
designed.28 Metastatic RCC patients received 800 mg 
pazopanib orally on a daily schedule. Eligibility required 
metastatic or locally recurrent predominant clear cell RCC, 
treatment-naïve or cytokine/bevacizumab refractory patients, 
and measurable disease by Response Evaluation Criteria in 
Solid Tumors (RECIST). An RDT design was employed 
initially, with all subjects receiving study drug. Patients 
with stable disease at 12 weeks were randomized to either 
continue pazopanib or a placebo. After approximately 60 
patients had been entered, an interim analysis was performed. 
The overall response rate (ORR) in this group was 38%, 
and the Data Monitoring Committee recommended the trial 
be modified. The RTD approach was discontinued, and all 
patients received open-label drug until disease progression. 
The original sample size estimate as defined in the RTD 
study was utilized, namely, the progressive disease rate at 
16 weeks post-randomization.
There were 225 patients entered into this trial, including 
the 55 patients from the RDT portion. The ORR was 35% 
(95% confidence interval [CI]: 28%–41%), when assessed 
by an independent review committee (IRC), and 34% (95% 
CI: 28%–40%) by investigator assessment. The ORR was 
similar in the treatment-naïve (34%, 95% CI: 26%–41%) and 
refractory patients (37%, 95% CI: 26%–49%). The median 
response duration was 68 weeks, and median progression free 
survival (PFS) 52 weeks (95% CI: 44–60 weeks).
Pazopanib was well tolerated, and the most common 
adverse events reported included diarrhea, fatigue, and hair 
depigmentation. Elevations of hepatic enzymes were seen, 
with increases of alanine aminotransferase (ALT) (54%) 
and/or aspartate aminotransferase (AST) (53%). Grade 3 or 4 
  elevations occurred in 7% and 10% of patients, respectively.
These Phase II results demonstrated significant clini-
cal activity in patients with metastatic clear cell RCC. In 
view of previous reports documenting tumor regression 
and improved PFS in metastatic RCC patients receiving 
sunitinib,15 sorafenib,16 or bevacizumab,20 this type of clini-
cal result should have been expected. The RDT design was 
therefore not optimal, since it required discontinuation of an 
active agent in the setting of stable disease and/or an evolv-
ing clinical response.
Phase iii randomized trial
Demonstration of pazopanib’s clinical benefit in metastatic 
RCC required a randomized, double-blind,   placebo-controlled 
Phase III trial.17 This pivotal study was designed and con-
ducted at a time when standard therapy for metastatic RCC 
was in transition. This transition occurred at different times 
in different areas of the world. The study was placebo-
controlled in order to definitively establish the activity of 
pazopanib, and provided placebo subjects the opportunity 
to crossover to pazopanib upon progression. When suni-
tinib or sorafenib were made available in various regions, 
enrolment ceased, unless access to the new agent was not 
possible. Untreated or cytokine refractory/intolerant patients 
with metastatic clear cell RCC were eligible. PFS based on 
IRC review was the primary endpoint. Secondary endpoints 
included ORR, OS, and toxicity. 435 patients (233 untreated, 
202 previous cytokine therapy) were randomized (2:1 ratio) Cancer Management and Research 2011:3 submit your manuscript | www.dovepress.com
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to either pazopanib 800 mg once daily (n = 290) or a placebo 
(n = 145). At the time of progression patients on the placebo 
arm were unblinded, and were then eligible for crossover 
to open-label pazopanib (extension trial, VEG107769). 
  Blinding was discontinued for all subjects after the final PFS 
analysis, and placebo-treated subjects without progressive 
disease had the option to receive pazopanib (VEG107769). 
The trial design permitted detection of an 80% improvement 
in PFS and 50% improvement in OS.
The study results have been updated on several 
occasions.17,29,30 The two arms were well balanced, and 95% of 
patients were either favorable or intermediate risk (MSKCC 
criteria).10 All patients had clear cell (90%) or predominantly 
clear cell histology (10%). Prior nephrectomy had been 
performed in approximately 90% of patients. The intent-to-
treat population included 233 untreated and 202 cytokine 
refractory patients. The study demonstrated improvement 
in median PFS for patients receiving pazopanib compared 
with the placebo group (9.2 months vs 4.2 months, hazard 
ratio [HR] for progression: 0.46, P , 0.0000001). This dif-
ference was more pronounced in treatment-naïve patients 
(11.1 months vs 2.8 months, HR: 0.40, P , 0.0000001) than 
in the cytokine refractory group (7.4 months vs 4.2 months, 
HR: 0.54, P , 0.001). A prespecified analysis of trial sub-
groups demonstrated that improvement of PFS was indepen-
dent of age, performance status, gender, and MSKCC risk 
group. The data for the various MSKCC risk groups are not 
yet available.
ORR was higher in all patients receiving pazopanib com-
pared with the control group (30% vs 3%). In treatment-naïve 
subjects, the ORR was 32% vs 4% for the placebo group. 
The median response duration was 59 weeks.
Selected efficacy data reported in various first-line Phase 
II/III trials of VEGF/VEGFR inhibitors in metastatic RCC 
patients (excluding the temsirolimus trial) are summarized in 
Table 2 (PFS), and Table 3 (OS). The ORR in   treatment-naïve 
patients varies between 5.2% and 47% depending upon the 
trial, agent utilized, and type of analysis (independent vs 
investigator). The most active agent appears to be sunitinib, 
with an ORR of 37% (47% investigator assessment).15,34 The 
ORR observed with pazopanib appears similar (32% vs 37%). 
Responses appear to be durable with all agents, with median 
response durations between 11.0 months and 14.0 months.
An interim survival analysis in the pazopanib Phase III 
trial initially reported a median OS of 21.1 months for 
pazopanib vs 18.7 months for the placebo patient group (HR: 
0.73, one-sided P = 0.02).17 Final OS data are available, and 
revealed a median OS of 22.9 months for the pazopanib 
vs 20.5 months in the placebo cohort (HR: 0.91, 95% CI: 
0.71  –1.16, stratified log rank P = 0.224).29 A high rate of 
secondary therapy in placebo patients compared with those 
randomized to pazopanib was reported (66% vs 30%), with 
54% of the placebo group ultimately receiving pazopanib.29 
In an inverse probability censoring weighted analysis which 
adjusts for the activity of pazopanib vs placebo, pazopanib 
therapy was associated with a 50% reduction in the risk of 
death.
Direct comparisons between the various trial results are 
not possible in view of the different trial designs and patient 
populations treated. Since the trials were conducted using 
similar endpoints and evaluation methods, the PFS data 
from these studies is illustrated in Figure 3. The effect of 
pazopanib on PFS appears comparable to that of the other 
anti-angiogenic agents in either treatment-naïve or cytokine 
pretreated subjects.
The pazopanib data have been compared37 to the Phase III 
trial results with sunitinib,15,34 sorafenib,16,38 and bevacizumab 
plus IFN-α.20,35 The adjusted indirect comparison methodol-
ogy was utilized. Patient characteristics were reported as 
similar across the various trials. This approach suggested that 
pazopanib is superior to IFN-α with a PFS HR (HR: 0.50, 95% 
CI: 0.31–0.81). In treatment-naïve patients, the indirect PFS 
Table 2 Progression free survival in frontline metastatic renal cell cancer randomized trials
Clinical trial/ 
Agent or regimen
Sunitinib  
vs IFN-α15  
(n = 750)
Bevacizumab+	
 IFN-α vs IFN-α
Pazopanib  
vs placebo17  
(n = 233)
Sorafenib  
vs IFN-α32  
(n = 189)
Sorafenib ±  AMG38633 
(3.0, 10 mg)  
(n = 151) Avoren20  
(n = 649)
CALGB 9020631  
(n = 732)
Sunitinib,  
bevacizumab + iFN-α,  
sorafenib, pazopanib
11.0 mos 10.2 mos 8.5 mos 11.1 mos 5.7 mos 9.0 mos
iNF-α, placebo,  
AMG 386 + sorafenib
5.0 mos 5.4 mos 5.2 mos 2.8 mos 5.6 mos 8.5, 9.0 mos
P value ,0.001 ,0.0001 ,0.0001 ,0.0001 0.504 0.532
Abbreviation: iNF-α, interferon-alpha.Cancer Management and Research 2011:3 submit your manuscript | www.dovepress.com
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HR suggested pazopanib was not statistically different from 
sunitinib (HR: 0.93, 95% CI: 0.56–1.56) or bevacizumab plus 
IFN-α (HR: 0.79, 95% CI: 0.48–1.32). In cytokine refractory 
patients, the indirect PFS HR suggests that pazopanib is not 
different from sorafenib (HR: 0.98, 95% CI: 0.61–1.58). 
  Further information from comparative randomized trials is 
now required to validate such comparisons. Currently, signifi-
cant improvement in PFS is a surrogate endpoint accepted as 
demonstrating clinical benefit of therapy in metastatic RCC 
patients, and appears to correlate with OS.39 The ultimate 
effect on survival however, remains a critical determinant 
of effectiveness. Comparisons of OS data were not reported 
by this group.
Phase ii pazopanib trials:  
refractory patients
Recently, several groups have examined the efficacy of 
pazopanib in RCC patients who have progressed on other 
targeted agents including TKIs, bevacizumab, and mam-
malian target of rapamycin inbitors.40,41 A Phase II trial in 44 
patients who had progressed or were intolerant of first-line 
sunitinib or bevacizumab was reported by Reeves et al.40 
These results are summarized in Table 4 and suggest 
pazopanib has activity in this subset of patients. A report 
from MD Anderson Hospital41 retrospectively reviewed 88 
consecutive refractory RCC patients who had received one 
or more targeted therapies which included sunitinib (78%), 
sorafenib (40%), temsirolimus (20%), everolimus (51%), or 
bevacizumab (26%). This was a heavily pretreated group, 
with 26% having also received prior chemotherapy, and 16% 
prior cytokines. In patients failing one prior agent, an ORR 
of 42% was found, in contrast to 18% in patients failing more 
than one targeted treatment. In both reports, the toxicity of 
pazopanib was similar to that noted previously. Seven percent 
and 10% of patients discontinued pazopanib secondary to 
adverse drug events, respectively. These two reports suggest 
pazopanib has clinical activity not only in the cytokine refrac-
tory patient, but also in patients failing targeted agents.
Phase i pazopanib combination trials
Several Phase I trials are in progress investigating admin-
istration of pazopanib with other targeted agents, including 
bevacizumab (NCT 00992121)42 and everolimus (NCT 
01184326).43 A recent report44 summarized the results of a 
phase I dose escalation trial combining temsirolimus and 
pazopanib to define the combination’s dose limiting toxicity 
(DLT). Solid tumor patients were eligible. The starting dose 
level included temsirolimus administered at a dose of 15 mg 
intravenously weekly, and pazopanib 400 mg per os daily. 
Table 3 Overall survival in randomized trials: frontline metastatic renal cell cancer patients
Clinical trial/ 
Agent or regimen
Sunitinib vs IFN-α34 AVOREN35 CALGB 9020636 Sorafenib vs IFN-α32 Pazopanib vs placebo29
Sunitinib, bevacizumab+  
iFN-α, pazopanib
26.4 mos 23.3 mos 18.3 mos NR 22.9 mos
iNF-α, placebo 21.8 mos 21.3 mos 17.4 mos NR 20.5 mos
P value 0.051 0.1291 0.069 NA 0.224
Hazard ratio (95% Ci) 0.821 (0.673, 1.001) 0.91 (0.76, 1.10) 0.86 (0.73, 1.01) NA 0.91 (0.71, 1.16)
Abbreviations: CI, confidence interval; INF-α, interferon-alpha; mos, months.
Pazopanib vs Placebo17 (n = 435)a
(1st/2nd line)
Sunitinib vs IFN-α15 (n = 750)
(1st line)
IFN-α ± Bevacizumab (AVOREN)20
(n = 649)  (1st line)
IFN-α ± Bevacizumab (CALGB
90206)31 (n = 732) (1st line)
Sorafenib vs IFN-α32 (n = 189)
(1st line)
Sorafenib vs Placebo16 (n = 903)
(2nd line)
Sorafenib ± AMG 38633 (n = 151)
(1st line)
0.40 (0.27, 0.60)b
0.415 (0.32, 0.539)
0.63 (0.52, 0.75)
0.67 (0.57, 0.79)
0.88 (0.61, 1.27)
0.44 (0.35, 0.55)
0.86 (0.68, 1.14)
1.2 1.0 0.8 0.6 0.4 0.2
Figure 3 Comparison of progression free survival data from recent phase ii and iii 
randomized clinical trials utilizing a variety of targeted agents in treatment-naïve or 
cytokine refractory patients with metastatic renal cell carcinoma.
Notes: apatient number; bhazard ratio (95% confidence interval).
Table 4 Phase ii trial pazopanib in patients refractory to sunitinib 
or bevacizumab40
All patients Previous 
sunitinib
Previous 
bevacizumab
Number 44 32 12
ORR 9 (20%) 5 (16%) 4 (33%)
DCR (CR + PR + SD) 31 (77%) 21 (66%) 10 (83%)
Median PFS 
(months)
9.23 (95%  
Ci: 5.42, NA)
12.06 (95%  
Ci: 6.14, NA)
8.05 (95%  
Ci: 2.76, 11.93)
Abbreviations: CI, confidence interval; ORR, overall response rate; DCR, disease 
control  rate;  NA,  not  available,  PFS,  progression  free  survival;  CR,  complete 
response; PR, partial response; SD, stable disease.Cancer Management and Research 2011:3 submit your manuscript | www.dovepress.com
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DLT was encountered at dose level 1, and a second dose 
level utilizing dose reductions of temsirolimus to 10 mg 
intravenously weekly and pazopanib to 200 mg daily was 
opened. DLT was again encountered. This trial enrolled only 
eight patients, but the authors suggest further development 
of this combination is not recommended secondary to grade 
3 fatigue and electrolyte disturbances which limited therapy 
at lower than optimal dose levels. The possibility pazopanib 
will resemble sunitinib and sorafenib when combined with 
other targeted agents and produce unacceptable toxicity is 
suggested by these preliminary observations, and the results 
of the other combination trials are needed to fully assess 
this issue.
Strategies to increase pazopanib efficacy
One approach to enhance the efficacy of current RCC therapy 
involves development of biomarkers for patient selection. 
Clinical response to pazopanib therapy varies between 
patients, and biomarkers possibly predictive of treatment 
outcome have recently been identified. Xu and colleagues45 
evaluated 27 single nucleotide polymorphisms within 
13 genes in 397 patients with RCC receiving pazopanib. 
The association with PFS and ORR was analyzed, with a 
recent update of the results examining correlations with 
OS46 (Table 5). Polymorphisms in IL-8, HIF1A, NR1l2, and 
VEGFA showed nominally significant association (P # 0.05) 
with PFS when compared with the wild-type genotypes. 
Similarly, polymorphisms in IL-8, fibroblast growth factor 
receptor 2, VEGFRA, FLT4, and NR1l2 in 241 patients 
were associated with OS. The data suggest germline vari-
ants in angiogenesis- and drug exposure-related genes may 
predict pazopanib efficacy in metastatic RCC patients, and 
may also be useful in predicting treatment failure in certain 
patients. Validation of these results is now required, but 
these approaches appear to provide an alternative strategy 
to enhance efficacy.
Finally, the relationship of drug exposure and efficacy of 
various TKIs in metastatic RCC has been suggested by several 
investigators.47 Suttle et al48 have investigated this relationship 
between pazopanib plasma concentrations at 4 and 12 weeks 
in patients treated in the phase II RTD pazopanib trial. A Cox 
regression analysis was utilized. Pharmacokinetic data were 
available from 205 patients. The median PFS in patients with 
a plasma pazopanib   concentration $20.6 µg/mL (n = 143) 
at week 4 was 49.4 weeks vs 20.3 weeks for those with 
lower values (n = 62, P = 0.0041). Additionally, pazopanib 
concentrations at week 4 above 20.6 µg/mL were associated 
with a significantly higher ORR (64/143 vs 11/62 or 45% 
vs 18%, P = 0.000017).These data suggest pazopanib con-
centrations .20.6 µg/mL may be associated with improved 
efficacy. Prospective studies to optimize pazopanib exposure 
in non-responding patients who have levels #20.6 µg/mL 
would be of interest.
Comparative Phase iii pazopanib trials
Several Phase III trials comparing pazopanib and sunitinib 
are in progress, and will provide important information 
on the comparative efficacy and tolerability of these two 
TKIs. VEGF pathway inhibitors produce a constella-
tion of common side effects including fatigue, diarrhea, 
hypertension, and nausea. Potential differences between 
adverse event profiles may reflect the mechanisms of 
action, types of targets inhibited, potency, VEGF pathway 
inhibition selectivity, and pharmacokinetic differences. In 
the case of pazopanib, a Phase III trial directly comparing 
pazopanib and sunitinib is underway. This international 
blinded controlled trial (COMPARZ trial) randomizes 
untreated patients with metastatic clear cell RCC to either to 
pazopanib 800 mg daily or sunitinib 50 mg/day for 4 weeks 
on and 2 weeks off therapy.49 The study is adequately pow-
ered (n = 876) for noninferiority, and will provide infor-
mation on the efficacy and, importantly, the tolerability of 
Table 5 Genotypes for single nucleotide polymorphisms associated with pazopanib efficacy45,46
Polymorphisms Progression free survival Overall survival
Median (weeks) P value Median (mos) P value
iL-8  AA 48 0.009 29.6 0.002
2767 A.T TT 27 14.8
HiF1A GG 44 0.03 NA –
1790 G.A TT 20 NA
veGFA GG NA – 25.3 0.004
1154 A.G AA NA 16.7
NR1l2  CC 48 0.07 NA –
-25385 C.T TT 58 NA
Abbreviations: HiF1A, Hypoxia-inducible factor 1, alpha subunit; iL-8, interlukin-8; NA, not available; veGFA, vascular endothelial growth factor A.Cancer Management and Research 2011:3 submit your manuscript | www.dovepress.com
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pazopanib compared with the most frequently used agent 
in metastatic RCC patients.
A second Phase III trial is underway to examine patient 
preferences with regard to initial therapy for metastatic RCC 
(PISCES trial).50 The design involves a randomized double 
blind, crossover trial in which 160 patients will receive either 
pazopanib or sunitinib at standard doses for two 10-week 
periods separated by a 2 week wash out phase. The trial will 
assess the tolerability and safety of these two TKIs and utilize 
patient reported outcomes to investigate differences.
Pazopanib safety and tolerability
Patients in the Phase II pazopanib RTD trial,28 tolerated 
therapy without difficulty. The most common adverse events 
reported included diarrhea, fatigue, and hair depigmentation. 
Laboratory abnormalities reported included elevated ALT 
(54%) and AST (53%), with $grade 3 elevations noted in 
7% and 9% of patients, respectively. In contrast, only mild 
hematologic toxicity (#grade 2) was encountered, with 
neutropenia and thrombopenia reported in 27% and 26% of 
patients, respectively.
This toxicity profile was confirmed in the Phase III piv-
otal trial comparing pazopanib to a placebo.17 In this study, 
pazopanib was also well tolerated. Table 6 summarizes the 
most common adverse events (all grades) experienced by 
patients in both treatment arms. These included diarrhea 
(52%), hypertension (40%), and hair color changes (38%). 
Grade 3 and 4 adverse events were uncommon. Hand-foot 
syndrome, arterial thrombotic events, hypothyroidism, pro-
teinuria, and stomatitis were noted in 3%–9% of patients. 
The most common laboratory abnormalities observed 
were grade 2 or less hepatic enzyme abnormalities and 
  hyperglycemia. In a subsequent report,30 the frequency 
and severity of adverse events did not change despite a 30% 
increase in cumulative pazopanib exposure.
Severe hepatic toxicity (grade 3 or worse) has been 
reported in 4%–12% of patients receiving pazopanib.28 
Results of a meta-analysis investigating hepatic toxicity 
related to pazopanib are now available.51 The studies ana-
lyzed included trials in which the pazopanib starting dose 
was 800 mg daily. Summary incidence rates, RR, and 95% 
CI were calculated using a fixed-effects or random-effects 
model. Eight trials involving 1155 patients with various 
solid tumors were included in the analysis. The incidence of 
ALT elevation was 41.7% (95% CI: 33.9–49.9) with 8.2% 
(95% CI: 5.9–11.3) characterized as high grade ($grade 3). 
A significant increase in high grade ALT elevation in RCC 
patients (10.9% vs 5.7%, P = 0.012) was noted. The   incidence 
of AST elevation was 39.3% (95% CI: 30.2–49.2) with 
6.4% (95% CI: 4.6–8.8) being high grade. In this case, no 
differences between RCC and non-RCC patients (7.4% vs 
4.8%, P = 0.22) were found. When compared to controls, an 
increased risk of high grade ALT elevation (RR: 7.95, 95% 
CI: 2.22–28.55, P = 0.001) and high grade AST elevation 
(RR: 9.01, 95% CI: 1.71–47.50, P = 0.01) were noted. The 
authors conclude pazopanib administration may be associated 
with a risk of $grade 3 hepatotoxicity, and the frequency 
may be dependent upon tumor type.
The most common adverse events associated with 
pazopanib, sunitinib, and bevacizumab plus IFNα are sum-
marized in Table 7. Grade 3 hepatic toxicity may be more fre-
quent with pazopanib than with other TKIs such as sunitinib. 
In contrast, neutropenia and thrombocytopenia appear less 
frequent. Such comparisons of toxicity must be investigated 
prospectively, however, the adverse event profiles of these 
three treatments have been indirectly compared.37 Adverse 
events were common with all agents (92%–99%). The rates 
of serious adverse events were also similar among these 
treatments (27%–34%). The frequency of $grade 3 adverse 
events was lower with pazopanib (44%, 95% CI: 40%–48%) 
Table 6 Phase iii trial of pazopanib versus placebo in metastatic 
renal  cell  carcinoma  –  selected  adverse  events  and  clinical 
chemistry abnormalities17,29,30
Pazopanib Placebo
All grades $grade 3 All grades $grade 3
Adverse event
Any event 92% 41% 74% 20%
Diarrhea 52% 4% 9% ,1%
Hypertension 40% 4% 10% 1%
Hair color changes 38% ,1% 3% 0
Nausea 26% ,1% 9% 0
vomiting 21% 2% 8% 2%
Fatigue 19% 2% 8% 2%
Asthenia 14% 3% 8% 0
Bleeding 13% 2% 5% 0
Hand-foot 6% NS ,1% NS
Headache 10% 0 5% 0
Chemistry
increased ALT 53% 12% 22% 1%
increased AST 53% 8% 19% ,1%
Hyperglycemia 41% ,1% 33% 1%
increased bilirubin 36% 4% 10% 2%
Hypophosphatemia 34% 4% 11% 0
Hypocalcemia 33% 2% 26% 1%
Hypoglycemia 17% ,1% 3% 0
Neutropenia 34% 2% 2% 0
Thrombopenia 32% 1% 5% ,1%
Proteinuria 9% NS 0 NS
Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase; 
NS, not stated.Cancer Management and Research 2011:3 submit your manuscript | www.dovepress.com
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compared to sunitinib (67%, 95% CI: 62%–71%) or 
bevacizumab plus IFN-α (60%, 95% CI: 55%–66%). This 
type of indirect comparison method suggests there may 
be differences between these agents, even including class 
effects such as hypertension. Safety comparisons must be 
interpreted based on the length of exposure to drug as well 
as other trial variables.
The health-related quality of life (HRQOL) data from 
the Phase III pazopanib vs placebo trial are also of interest 
when considering patient tolerability.52 HRQOL outcome 
was assessed using European Organization for Research 
and Treatment of Cancer Quality of Life Questionnaire 
(QLQ-C30) and EQ-5D index and visual analog scale. The 
time to $20% decline from baseline HRQOL was estimated 
for all patients, by prior therapy, and stratified by response 
(RECIST). The authors noted placebo treated patients were 
more likely to experience $20% HRQOL decline (QLQ-C30) 
(HR: 0.77, 95% CI: 0.57–1.03, P = 0.0817). Patients with 
RECIST responses experienced significantly less HRQOL 
deterioration compared to progressive disease patients. These 
results supporting the tolerability profile of pazopanib and 
suggest patients who had tumor response also experienced 
better HRQOL compared to those without response.
Conclusion: role of pazopanib  
in RCC therapy
In the Phase III randomized double-blind placebo-controlled 
trial, pazopanib treatment produced a highly significant 
PFS improvement for either treatment-naïve or cytokine 
pretreated patients. The efficacy and safety results from this 
study were similar to those from the Phase II nonrandom-
ized open label RTD trial in a similar population. Certain 
adverse reactions are common to the anti-VEGF agent class, 
however, their incidence and severity varies widely. The 
potential difference in the safety profiles of these agents 
provides treatment options for patients with advanced RCC. 
Pazopanib represents a treatment option with comparable 
efficacy, and potential important differences in tolerability vs 
the current standard of care. As such, it appears to represent 
a valuable addition to the treatment of advanced RCC. The 
following observations on efficacy and toxicity are relevant 
when considering the role of pazopanib in patients with 
metastatic clear cell RCC:
Efficacy of pazopanib
•	 A large and very significant improvement in PFS was 
demonstrated with pazopanib compared to a placebo in 
patients with advanced metastatic RCC. The concordance 
of the IRC and the investigator assessments demonstrate 
the robust nature of the findings.
•	 Subgroup analyses demonstrate PFS improvement was 
consistent across multiple clinically relevant subgroups. 
Importantly, these improvements were seen in prespeci-
fied groups, including both treatment-naïve and cytokine 
refractory patients.
•	 The median PFS reported in the Phase II RTD 
study (10.4 months) was similar to that reported 
in  the  pivotal  study  (all  patients:  9.2  months, 
Table 7 Selected adverse events (all grades and $grade 3): sunitinib, bevacizumab + iFN-α, and pazopanib pivotal trials
Treatment setting/ 
Adverse event
First-line First-line First/second line
Sunitinib15,34 Bevacizumab + IFN-α20 Pazopanib17,29,30
All grades (%) $grade 3 (%) All grades (%) $grade 3 (%) All grades (%) $grade 3 (%)
Fatigue 54 11 33 12 20 2
Asthenia 20 7 32 10 14 3
Diarrhea 61 9 20 2 52 4
Hemorrhage 18a 1 33 3 14b 1
Hand-foot syndrome 29 9 – – 6 ,1
Hypertension 30 12 26 3 40 4
Decline LveF 13 3 NS NS ,1 ,1
Neutropenia 77 18 7 4 36 1
Thrombocytopenia 68 9 6 2 34 1
increased ALT 51 3 NS NS 53 13
increased AST 56 2 NS NS 53 8
increased total bilirubin 20 1 NS NS 36 4
Discontinuations due to  
adverse events
19 19c 14
Notes: aepistaxsis; ball causes; cbevacizumab discontinuation rate, rate for either agent 28%.
Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase; iNF-α, interferon-alpha; LveF, left ventricular ejection fraction; NS, not stated.Cancer Management and Research 2011:3 submit your manuscript | www.dovepress.com
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  treatment-naïve: 11.1 months), and resembles those of 
the current standard metastatic RCC therapy sunitinib 
(11 months in first-line).
•	 The survival data suggest a favorable trend associated 
with pazopanib treatment, in spite of significant crossover 
by subjects in the placebo arm.
•	 The median OS of placebo patients in the pivotal study 
was substantially longer than reported for a historical 
group of metastatic RCC patients receiving cytokines.53 
This may reflect the confounding effects of secondary 
therapy.
•	 The Phase II results in TKI refractory patients with 
pazopanib resemble those reported with other TKIs, and 
are consistent with a lack of cross resistance.
Safety of pazopanib
•	 The most common side effects of pazopanib include 
diarrhea, hypertension, hair color changes, nausea, 
fatigue, anorexia, and vomiting. Most adverse events 
are grade 1 or 2, and do not require discontinuation of 
therapy.
•	 The most common serious adverse events associated 
with pazopanib include diarrhea, dyspnea, pleural effu-
sion, abdominal pain, and vomiting. More serious liver 
function abnormalities, arterial/thrombotic events, and 
hemorrhagic events have also been reported.
•	 The most common laboratory abnormalities produced 
include grade 1 or 2 ALT, AST, and bilirubin elevations, 
hyperglycemia, and electrolyte abnormalities. The most 
common serious laboratory abnormalities ($grade 3) 
were hepatic enzyme elevations. Cytopenias occur in 
pazopanib treated patients, but $grade 3 hematologic 
toxicity is seldom seen.
•	 Grade 3 or greater elevations of hepatic enzymes occur 
in from 8% to 13% of patients treated with pazopanib. 
The time course of this development is well character-
ized, and recommendations for monitoring liver func-
tions are available. Importantly, these liver enzyme 
elevations will generally normalize with adequate 
follow-up. In patients who continue to receive pazopanib 
despite transaminase elevations, adaptation has been 
noted.
•	 Fatal liver toxicity related to pazopanib is rare (0.05%–
0.1%), and has also been reported with other TKIs such 
as sunitinib and sorafenib.
•	 Adverse events previously described with other TKIs, 
such as cardiac/cerebral ischemia, hemorrhage, and bowel 
perforation, are also observed with pazopanib. However, 
no evidence of left ventricular dysfunction has been 
reported secondary to pazopanib administration.
•	 Patients receiving pazopanib may exhibit differences in 
tolerability when compared to individuals treated with 
the other approved anti-VEGF TKIs. This includes a pos-
sible lower incidence of mucositis, hand-foot syndrome, 
fatigue, and hematologic toxicity (Table 6).
In summary, the overall risk benefit of pazopanib 
appears favorable. The available data demonstrate 
pazopanib has efficacy in patients with metastatic RCC 
who are either treatment-naïve or cytokine refractory. The 
significant improvement of PFS compared to a placebo 
noted in the pivotal Phase III trial is an acceptable surro-
gate of clinical benefit. The final analysis of OS failed to 
demonstrate significant improvement, however, the influ-
ence of crossover and the confounding effects of second-
ary therapy may be responsible factors. The final median 
OS for pazopanib patients in the combined population of 
treatment-naive and cytokine refractory individuals was 
22.4 months, for the placebo subjects was 20.1 months. 
The OS of this latter group is different from historical data 
for metastatic RCC patients who have received either a 
placebo or cytokine therapy. This may be a reflection of 
the crossover study design.
These benefits should be examined in the context of 
possible pazopanib associated toxicity. Pazopanib’s safety 
profile is well documented, and the majority of adverse events 
are grade 1 or 2. The frequency of grade 3 and 4 events is 
generally low. The majority of associated adverse events 
are easily managed. It is important to note that the adverse 
events reported with pazopanib have also been reported with 
the other agents approved for metastatic RCC. The incidence 
and severity of various adverse events varies between agents, 
with these differences potentially impacting drug utilization. 
The relatively low incidence of severe myelosuppression, 
hand-foot syndrome, stomatitis, and fatigue compared with 
the safety profile of other agents of this class such as suni-
tinib in metastatic RCC position pazopanib as a potential 
therapeutic option. The COMPARZ clinical trial which 
compares the safety and efficacy of pazopanib and sunitinib 
will provide the comparative data required to determine 
whether pazopanib has similar efficacy and an improved 
toxicity profile. Generally efficacy guides therapeutic deci-
sions when toxicity is equivalent.
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